246 related articles for article (PubMed ID: 35493991)
1. New quinoxaline-based VEGFR-2 inhibitors: design, synthesis, and antiproliferative evaluation with
Alanazi MM; Elkady H; Alsaif NA; Obaidullah AJ; Alkahtani HM; Alanazi MM; Alharbi MA; Eissa IH; Dahab MA
RSC Adv; 2021 Sep; 11(48):30315-30328. PubMed ID: 35493991
[TBL] [Abstract][Full Text] [Related]
2. Discovery of new 3-methylquinoxalines as potential anti-cancer agents and apoptosis inducers targeting VEGFR-2: design, synthesis, and
Alanazi MM; Alaa E; Alsaif NA; Obaidullah AJ; Alkahtani HM; Al-Mehizia AA; Alsubaie SM; Taghour MS; Eissa IH
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1732-1750. PubMed ID: 34325596
[TBL] [Abstract][Full Text] [Related]
3. New [1,2,4]triazolo[4,3-c]quinazoline derivatives as vascular endothelial growth factor receptor-2 inhibitors and apoptosis inducers: Design, synthesis, docking, and antiproliferative evaluation.
Azab AE; Alesawy MS; Eldehna WM; Elwan A; Eissa IH
Arch Pharm (Weinheim); 2022 Oct; 355(10):e2200133. PubMed ID: 35822666
[TBL] [Abstract][Full Text] [Related]
4. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
5. A new class of anti-proliferative activity and apoptotic inducer with molecular docking studies for a novel of 1,3-dithiolo[4,5-
Ismail MA; Abusaif MS; El-Gaby MSA; Ammar YA; Ragab A
RSC Adv; 2023 Apr; 13(18):12589-12608. PubMed ID: 37101951
[TBL] [Abstract][Full Text] [Related]
6. Design, Synthesis, In Silico and In Vitro Studies of New Immunomodulatory Anticancer Nicotinamide Derivatives Targeting VEGFR-2.
Yousef RG; Eldehna WM; Elwan A; Abdelaziz AS; Mehany ABM; Gobaara IMM; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
Molecules; 2022 Jun; 27(13):. PubMed ID: 35807326
[TBL] [Abstract][Full Text] [Related]
7. Targeting VEGFR-2 by new quinoxaline derivatives: Design, synthesis, antiproliferative assay, apoptosis induction, and in silico studies.
Alsaif NA; Mahdy HA; Alanazi MM; Obaidullah AJ; Alkahtani HM; Al-Hossaini AM; Al-Mehizi AA; Elwan A; Taghour MS
Arch Pharm (Weinheim); 2022 Feb; 355(2):e2100359. PubMed ID: 34862634
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, anticancer effect and molecular modeling of new thiazolylpyrazolyl coumarin derivatives targeting VEGFR-2 kinase and inducing cell cycle arrest and apoptosis.
Mohamed TK; Batran RZ; Elseginy SA; Ali MM; Mahmoud AE
Bioorg Chem; 2019 Apr; 85():253-273. PubMed ID: 30641320
[TBL] [Abstract][Full Text] [Related]
9. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
10. Design and Synthesis of New Quinoxaline Derivatives as Potential Histone Deacetylase Inhibitors Targeting Hepatocellular Carcinoma:
Ma C; Taghour MS; Belal A; Mehany ABM; Mostafa N; Nabeeh A; Eissa IH; Al-Karmalawy AA
Front Chem; 2021; 9():725135. PubMed ID: 34631658
[TBL] [Abstract][Full Text] [Related]
11. Discovery of new quinoxaline-2(1H)-one-based anticancer agents targeting VEGFR-2 as inhibitors: Design, synthesis, and anti-proliferative evaluation.
El-Adl K; Sakr HM; Yousef RG; Mehany ABM; Metwaly AM; Elhendawy MA; Radwan MM; ElSohly MA; Abulkhair HS; Eissa IH
Bioorg Chem; 2021 Sep; 114():105105. PubMed ID: 34175720
[TBL] [Abstract][Full Text] [Related]
12. New nicotinamide derivatives as potential anticancer agents targeting VEGFR-2: design, synthesis,
Yousef RG; Eissa IH; Elkady H; Eldehna WM; Mehany ABM; Nabeeh A; Ibrahim IM; Elwan A; El-Zahabi MA
J Biomol Struct Dyn; 2023 Dec; ():1-18. PubMed ID: 38100580
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, anti-proliferative evaluation, docking, and MD simulation studies of new thieno[2,3-
El-Metwally SA; Elkady H; Hagras M; Husein DZ; Ibrahim IM; Taghour MS; El-Mahdy HA; Ismail A; Alsfouk BA; Elkaeed EB; Metwaly AM; Eissa IH
RSC Adv; 2023 Jul; 13(33):23365-23385. PubMed ID: 37545598
[TBL] [Abstract][Full Text] [Related]
14. New quinoxaline derivatives as VEGFR-2 inhibitors with anticancer and apoptotic activity: Design, molecular modeling, and synthesis.
Alsaif NA; Dahab MA; Alanazi MM; Obaidullah AJ; Al-Mehizia AA; Alanazi MM; Aldawas S; Mahdy HA; Elkady H
Bioorg Chem; 2021 May; 110():104807. PubMed ID: 33721808
[TBL] [Abstract][Full Text] [Related]
15. Discovery of new pyrimidine-5-carbonitrile derivatives as anticancer agents targeting EGFR
Nasser AA; Eissa IH; Oun MR; El-Zahabi MA; Taghour MS; Belal A; Saleh AM; Mehany ABM; Luesch H; Mostafa AE; Afifi WM; Rocca JR; Mahdy HA
Org Biomol Chem; 2020 Oct; 18(38):7608-7634. PubMed ID: 32959865
[TBL] [Abstract][Full Text] [Related]
16. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
17. Discovery of new thiazolidine-2,4-dione derivatives as potential VEGFR-2 inhibitors:
Eissa IH; Elkady H; Rashed M; Elwan A; Hagras M; Dahab MA; Taghour MS; Ibrahim IM; Husein DZ; Elkaeed EB; Al-Ghulikah HA; Metwaly AM; Mahdy HA
Heliyon; 2024 Jan; 10(2):e24005. PubMed ID: 38298627
[TBL] [Abstract][Full Text] [Related]
18. New Carbothioamide and Carboxamide Derivatives of 3-Phenoxybenzoic Acid as Potent VEGFR-2 Inhibitors: Synthesis, Molecular Docking, and Cytotoxicity Assessment.
Heriz MH; Mahmood AAR; Tahtamouni LH; AlSakhen MF; Kanaan SI; Saleh KM; Yasin SR
Curr Cancer Drug Targets; 2024 May; ():. PubMed ID: 38747227
[TBL] [Abstract][Full Text] [Related]
19. New Thieno[2,3-d]pyrimidines as Anticancer VEGFR-2 Inhibitors with Apoptosis Induction: Design, Synthesis, and Biological and In Silico Studies.
Sobh EA; Dahab M; Elkaeed E; Alsfouk B; Ibrahim I; Metwaly AM; Eissa I
Med Chem; 2024 May; ():. PubMed ID: 38798211
[TBL] [Abstract][Full Text] [Related]
20. Discovery of new anticancer thiourea-azetidine hybrids: design, synthesis, in vitro antiproliferative, SAR, in silico molecular docking against VEGFR-2, ADMET, toxicity, and DFT studies.
Parmar DR; Soni JY; Guduru R; Rayani RH; Kusurkar RV; Vala AG; Talukdar SN; Eissa IH; Metwaly AM; Khalil A; Zunjar V; Battula S
Bioorg Chem; 2021 Oct; 115():105206. PubMed ID: 34339975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
